Anti-transthyretin (ttr) binding proteins and uses thereof
OwnerJanett KÖPPEN, Stephan SCHILING +5inventors
InventorsJanett KÖPPEN, Stephan SCHILING, Anja SCHULZE, Jens-Ulrich RAHFELD, Michael WERMANN, Martin KLEINSCHMIDT, Holger CYNIS
Life of this patent
Estimating the term…
Abstract
Transthyretin amyloidosis is characterized by progressive deposition of the plasma protein transthyretin in the myocardium, peripheral nerves and/or other tissues, which can ultimately lead to congestive heart failure, polyneuropathy and death. The present invention provides binding proteins that can specifically bind to an isoaspartate residue in a transthyretin protein as well as their therapeutic, diagnostic and prognostic uses.
Claims18
A binding protein that specifically binds to an isoaspartate-modified transthyretin wherein the aspartate at position 38, with reference to the numbering of SEQ ID NO:
- 1, has been post-translationally modified into an L-isoaspartate.
(canceled)
Dependencies are inferred from the claim text.